Kodama, Mitsuo, Kodama, Toshiko · In vivo (Athens, Greece) · 2006
This study describes a clinic's experience treating patients with interstitial pneumonia (a lung condition) using high-dose vitamin C infusions combined with hormones and antibiotics since 1996. The authors discuss four main challenges they encountered: deciding whether to continue treatment when patients seemed stable, dealing with bacteria becoming resistant to antibiotics, observing bone marrow damage in one patient, and noting one patient developed breast cancer during treatment.
This paper presents one clinic's long-term observations on treating a disease classified as both interstitial pneumonia and ME/CFS, offering clinical data on treatment tolerability and potential serious adverse effects (bone marrow decline, malignancy) that deserve careful consideration. Understanding both the benefits and harms of proposed treatments is essential for ME/CFS patients evaluating their options.
This case-series study does not establish that megadose vitamin C, dehydroepiandrosterone, or continuous antibiotics are effective treatments for ME/CFS, nor does it prove that interstitial pneumonia and ME/CFS are the same disease. The lack of a concurrent control group, absence of blinding, and small sample size prevent causal inference about treatment efficacy. Observed complications (bone marrow fibrosis, cancer) cannot be attributed definitively to any specific treatment component.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →